Macro Factors Take a Toll on Cutera Earnings, Analyst Slashes Price Target by 61%

  • Earlier this week, Cutera Inc CUTR reported interim FY22 sales of $252 million to $253 million for full-year 2022, growing 15% to 16% over the prior year on a constant currency basis versus prior guidance of $255 million to $260 million, missing the consensus of $259 million.
  • Cantor Fitzgerald has downgraded the stock rating on CUTR to Neutral from Overweight and lowered the price target to $33 from $85.
  • The analyst said to be moving to the sidelines on CUTR's stock until macro headwinds (recessionary environment, FX) that it thinks will impact the company's business subsides and/or management can demonstrate that it can continue to grow the business through a down cycle. 
  • The analyst will reassess its investment thesis after the company releases full results for 4Q22 and 2022 on 28 February.
  • Price Action: CUTR shares are down 7.47% at $27.60 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsNewsGuidanceDowngradesHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!